Phenylalanine, /1-3,4-dihydroxy-,

Dopa — see Phenylalanine, dihydroxy-Dopplerite structure, 6, 849 Douglasite structure, 6, 846 Down s syndrome Alzheimer s disease, 6,770 DPP A process, 6,911 Drugs absorption metals, 6, 774... 

The neurotransmitter must be present in presynaptic nerve terminals and the precursors and enzymes necessary for its synthesis must be present in the neuron. For example, ACh is stored in vesicles specifically in cholinergic nerve terminals. It is synthesized from choline and acetyl-coenzyme A (acetyl-CoA) by the enzyme, choline acetyltransferase. Choline is taken up by a high affinity transporter specific to cholinergic nerve terminals. Choline uptake appears to be the rate-limiting step in ACh synthesis, and is regulated to keep pace with demands for the neurotransmitter. Dopamine [51 -61-6] (2) is synthesized from tyrosine by tyrosine hydroxylase, which converts tyrosine to L-dopa (3,4-dihydroxy-L-phenylalanine) (3), and dopa decarboxylase, which converts L-dopa to dopamine. 

FIGURE 27.5 Tyrosine is the biosynthetic precursor to a number of neurotransmitters. Each transformation is enzyme-catalyzed. Hydroxy-lation of the aromatic ring of tyrosine converts it to 3,4-dihydroxy phenylalanine (L-dopa), decarboxylation of which gives dopamine. Hy-droxylation of the benzylic carbon of dopamine converts it to norepinephrine (noradrenaline), and methy-lation of the amino group of norepinephrine yields epinephrine (adrenaline). 

Fraga, S., M. P. Serrao, and P. Soares-da-Silva. The L-3,4-dihydroxy-phenylalanine transporter in human and rat epithelial intestinal cells is a type 2 hetero amino add exchanger. Eur. J. Pharmacol. 2002, 441, 127—135. 

Tyrosine hydroxylase is the rate-limiting enzyme for the biosynthesis of catecholamines. Tyrosine hydroxylase (TH) is found in all cells that synthesize catecholamines and is a mixed-function oxidase that uses molecular oxygen and tyrosine as its substrates and biopterin as its cofactor [1], TH is a homotetramer, each subunit of which has a molecular weight of approximately 60,000. It catalyzes the addition of a hydroxyl group to the meta position of tyrosine, thus forming 3,4-dihydroxy-L-phenylalanine (l-DOPA). 

The interaction with both synthetic and naturally occurring amino acids has been studied extensively glycine (138, 173, 219-221), a-(173, 219) and /3-alanine (138, 220), sarcosine (219), serine (222), aspartic acid (138, 173, 222-226), asparagine (222), threonine (222), proline (219), hydroxyproline (219), glutamic acid (138, 222-225), glutamine (222), valine (219, 227), norvaline (219), methionine (222, 226), histidine (228, 229), isoleucine (219), leucine (219, 230), norleu-cine (219), lysine (222), arginine (222), histidine methyl ester (228), phenylalanine (138, 222), tyrosine (222), 2-amino-3-(3,4-dihydroxy-phenyl jpropanoic acid (DOPA) (222), tryptophan (222), aminoiso-butyric acid (219), 2-aminobutyric acid (219,231), citrulline (222), and ornithine (222). 

Figure 13.21 Mononuclear non-haem iron enzymes from each of the five families in structures which are poised for attack by 02. (a) The extradiol-cleaving catechol dioxygenase, 2,3-dihydroxy-biphenyl 1,2-dioxygenase (b) the Rieske dioxygenase, naphthalene 1,2-dioxygenase (c) isopenicillin N-synthase (d) the ot-ketoglutarate dependent enzyme clavaminate synthase and (e) the pterin-dependent phenylalanine hydroxylase. (From Koehntop et al., 2005. With kind permission of Springer Science and Business Media.)...

The drug melphalan (phenylalanine mustard, 11.33, R = R = Cl) is another good example of a nitrogen mustard that undergoes hydrolytic dechlorination. Melphalan administered to cancer patients gives rise to the monohydroxy (11.33, R = Cl, R = OH) and dihydroxy metabolites (11.33, R = R = OH), which were detected in the plasma with a combined AUC (area-under-the-curve) amounting to 29% of the AUC of the drug [68],... 

Methyldopa (dopa = dihydroxy-phenylalanine), as an amino acid, is transported across the blood-brain barrier, decarboxylated in the brain to a-methyldopamine, and then hydroxylat-ed to a-methyl-NE The decarboxylation of methyldopa competes for a portion of the available enzymatic activity, so that the rate of conversion of L-dopa to NE (via dopamine) is decreased. The false transmitter a-methyl-NE can be stored however, unlike the endogenous mediator, it has a higher affinity for a2- than for ai-receptors and therefore produces effects similar to those of clonidine. The same events take place in peripheral adrenergic neurons. 

L-Dopa. Dopamine itself cannot penetrate the blood-brain barrier however, its natural precursor, L-dihydroxy-phenylalanine (levodopa), is effective in replenishing striatal dopamine levels, because it is transported across the blood-brain barrier via an amino acid carrier and is subsequently decarboxy-lated by DOPA-decarboxylase, present in striatal tissue. Decarboxylation also takes place in peripheral organs where dopamine is not needed, likely causing undesirable effects (tachycardia, arrhythmias resulting from activation of Pi-adrenoceptors [p. 114], hypotension, and vomiting). Extracerebral production of dopamine can be prevented by inhibitors of DOPA-decarboxylase (car-bidopa, benserazide) that do not penetrate the blood-brain barrier, leaving intracerebral decarboxylation unaffected. Excessive elevation of brain dopamine levels may lead to undesirable reactions, such as involuntary movements (dyskinesias) and mental disturbances. 

Only a few important representatives of the non-proteinogenic amino acids are mentioned here. The basic amino acid ornithine is an analogue of lysine with a shortened side chain. Transfer of a carbamoyl residue to ornithine yields citrulline. Both of these amino acids are intermediates in the urea cycle (see p.l82). Dopa (an acronym of 3,4-dihydroxy-phenylalanine) is synthesized by hydroxyla-tion of tyrosine. It is an intermediate in the biosynthesis of catecholamines (see p.352) and of melanin. It is in clinical use in the treatment of Parkinson s disease. Selenocys-teine, a cysteine analogue, occurs as a component of a few proteins—e.g., in the enzyme glutathione peroxidase (see p.284). 

C. Dopamine is a precursor for norepinephrine and a neurotransmitter. Tyrosine is a precursor of dopamine and norepinephrine. Dopa (dihydroxy-phenylalanine) is a precursor of dopamine and subsequently also of norepinephrine. Glutamine can be converted to the neurotransmitter glutamic acid. 

The efficient resolution of /ra r-4,5-dihydroxy-l,2-dithiane into the two enantiomers in large quantities has been reported by the reaction of the racemic mixture with the amino acid iV-/-butoxycarbonyl-(5)-phenylalanine <1997TL7657>. By fractional crystallization, the (43, 53 )- and (4/J,5iJ)-esters were separated followed by hydrolysis, which provided the desired enantiomeric diols in excellent yield and >99% ee. These reactive diols provide isomerically pure analogs with interesting selectivity and therapeutic potential for example, 4,5-dihydroxy-l,2-dithiane derivatives have been reported to inhibit the replication of HIV-1 and HIV-2 (human immunodeficiency viruses). 

Whilst the term biogenic amine strictly encompasses all amines of biological origin, for the purpose of this article it will be employed to refer to the catecholamine (dopamine, noradrenaline) and serotonin group of neurotransmitters. These neurotransmitters are generated from the amino acid precursors tyrosine and tryptophan, respectively, via the action of the tetrahydrobiopterin (BH4)-dependent tyrosine and tryptophan hydroxylases. Hydroxylation of the amino acid substrates leads to formation of 3,4-dihydroxy-l-phenylalanine ( -dopa) and 5-hydroxytryptophan, which are then decarboxylated via the pyridoxalphosphate-dependent aromatic amino acid decarboxylase (AADC) to yield dopamine and serotonin [4]. In noradrenergic neurones, dopamine is further metabolised to noradrenaline through the action of dopamine-jS-hydroxylase [1]. 

Fig. 6.2.3a-c AADC assay using HPLC and EC detection of dopamine, a Standard mixture b serum control sample c serum AADC deficiency. DA Dopamine, L-Dopa 3,4-dihydroxy-l-phenylalanine... 

Homogeneous asymmetric hydrogenation is a practical synthetic method (27). The DIPAMP-Rh-catalyzed reaction has been used for the commercial production of (S)-DOPA [(5)-3-(3,4-dihydroxy-phenyl) alanine] used to treat Parkinson s disease (Monsanto Co. and VES Isis-Chemie) (Scheme 12) (27, 28). (S)-Phenylalanine, a component of the nonnutritive sweetener aspartame, is also prepared by en-antioselective hydrogenation (Anic S.p.A. and Enichem Synthesis) (29). A cationic PNNP-Rh(nbd) complex appears to be the best catalyst for this purpose (15c) (see Scheme 5 in Chapter 1). 

Some of the pathways of animal and bacterial metabolism of aromatic amino acids also are used in plants. However, quantitatively more important are the reactions of the phenylpropanoid pathway,173-1743 which is initiated by phenylalanine ammonia-lyase (Eq. 14-45).175 As is shown at the top of Fig. 25-8, the initial product from phenylalanine is trails-cinnam-ate. After hydroxylation to 4-hydroxycinnamate (p-coumarate) and conversion to a coenzyme A ester,1753 the resulting p-coumaryl-CoA is converted into mono-, di-, and trihydroxy derivatives including anthocyanins (Box 21-E) and other flavonoid compounds.176 The dihydroxy and trihydroxy methylated products are the starting materials for formation of lignins and for a large series of other plant products, many of which impart characteristic fragrances. Some of these are illustrated in Fig. 25-8. 

L-Dihydroxy-phenylalanine 102 Synthesis from piperonal, vanillin, or acrylonitrile and resolution Specific drug for Parkinson s disease... 

Figure 5. Anaerobic Decarboxylation of Phenylserine, Dihydroxy phenylalanine (DOPA), and Dihydroxyphenylserine (DOPS) by Supernatant from 20% Homogenate of Dog Kidney in 0.1 M Phosphate Buffer...

Hensley, K., Maidt, M. L., Pye, Q. N., Stewart, C. A., Wack, M., Tabatabaie, T., and Floyd, R. A. (1997). Quantitation of protein-bound 3-nitrotyrosine and 3,4-dihydroxy-phenylalanine by high-performance liquid chromatography with electrochemical array detection. Anal. Biochem. 251 187-195. 

---